Mindscape Collective is now The Consciousness Library. Same library, new name. You may need to sign in again. About the change
Skip to content

Andrea Schneider

3 papers in the library · 51 citations · publishing 1999-2025

Papers

Analysis of psilocybin and psilocin in Psilocybe subcubensis GUZMÁN by ion mobility spectrometry and gas chromatography–mass spectrometry

Forensic Science International January 1, 1999 Thomas Keller, Andrea Schneider, Priska Regenscheit et al. 50 citations

A new method using ion mobility spectrometry allows rapid analysis of psilocybin and psilocin in fungus material. Quantitative analysis was performed by gas chromatography-mass spectrometry after a simple one-step extraction: homogenizing dried fruit bodies in chloroform and derivatizing with MSTFA. The procedures are rapid and useful for analyzing psychotropic fungi for these compounds.

Implementation of a specialized neuroprognostication consultation program and associated provider attitudes: A survey-based study.

Resuscitation plus May 1, 2025 David Fischer, Sahily Reyes-Esteves, Connor Law et al. 1 citation

A specialized, interdisciplinary, and longitudinal neuroprognostication program for disorders of consciousness after cardiac arrest was associated with more favorable provider attitudes. Surveys of 545 neurologists and critical care providers showed that those exposed to the program, compared to historical and contemporary controls, more often rated neuroprognostication as useful (94% vs 69% and 68%) and comprehensive (94% vs 76% and 66%), and 63% rated the program as much better than the conventional model. The findings suggest that such a program may improve the practice of neuroprognostication.

Reductions in anxiety and depression symptoms in a subset of outpatients with problematic substance use who received ketamine-assisted psychotherapy: a two-year retrospective chart review.

Frontiers in Psychiatry January 1, 2023 Emily Whinkin, Therry Rose J Eparwa, Michelle C Julseth et al.

In patients with problematic substance use, ketamine-assisted psychotherapy (KAP) was associated with significant reductions in anxiety and depression symptoms, as measured by the GAD-7 and PHQ-9 scales. The average GAD-7 score decreased by 6.71 points, and the average PHQ-9 score decreased by 7.44 points. Improvements in psychosocial and spiritual well-being, measured by the NIH-HEALS scale, increased by an average of 5.13 points but were not statistically significant. Compared to the broader KAP patient population, those with problematic substance use showed significantly greater reductions in anxiety and depression. Undergoing one to six KAP sessions may be a useful therapy for reducing these symptoms in this population.